bell
The current prices are delayed by 15 mins, login to check live prices.
Morepen Laboratories Ltd share price logo

Morepen Laboratories Ltd

(MOREPENLAB)

₹79.894.04%

as on 04:01PM, 20 Dec 2024

Overview
News
Financials
Q2 2024 Results
Technicals

Morepen Laboratories Ltd Performance

  • Day's Low

    Day's High

    ₹79.06
    Day's Price Range
    ₹84.57
  • 52 Week's Low

    52 Week's High

    ₹38.55
    52-Week Price Range
    ₹100.9
1 Month Return+ 13.68 %
3 Month Return-3.47 %
1 Year Return+ 72.36 %
Previous Close₹83.25
Open₹83.70
Volume54.28L
Upper Circuit-
Lower Circuit-
Market Cap₹4,607.74Cr

Morepen Laboratories Ltd Key Statistics

P/E Ratio32.91
PEG Ratio21.79
Market Cap₹4,607.74 Cr
P/B Ratio2.42
EPS1.89
Dividend Yield0
SectorPharmaceuticals
ROE13.29

Morepen Laboratories Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
NA₹4,607.74 Cr85.71%0.53₹96 Cr₹1,690 Cr
NA₹435.76 Cr272.24%0.54₹28 Cr₹601 Cr
NA₹15.41 Cr278.33%0.50NANA
BUY₹23,100.09 Cr3.59%0.52NANA
NA₹706.49 Cr-0.07%0.57₹9 Cr₹179 Cr

Morepen Laboratories Ltd Mutual Fund Holdings

About Morepen Laboratories Ltd

Morepen Laboratories Limited is a pharmaceutical company based in India that develops and markets formulation products in numerous therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic, and neuropsychiatry. Their products include Loratadine Montelukast Sodium, Atorvastatin Calcium and Sultamicillin, along with new entries such as Kilbac Ducal, D Aclomore and Montelast-L. It currently has three state-of-the-art manufacturing plants in Himachal Pradesh, India, with the main plant in Parwanoo being USFDA-approved for Loratadine production. The company was established in 1984 and since then has filed 14 patents, including an international one on a new amorphous form of Lipitor Atorvastatin. Expansion plans from 1992-1993 saw the installation of bulk drugs from 162 MT to 245 MT and the launch of two new molecules – Ketrolac, Tromethamine and Omeprazole. In 1995-1996, the company increased bulk drug installation from 305 MT to 469 MT and launched Loratadine and Cisapride. The year 1996-1997 saw the commencement of their own formulation unit, while they filed an international patent on a new amorphous form of Atorvastatin, world’s largest selling drug in 2000-2001. In 2001-2002, their drug and drug intermediate installation reached 1251 MT, with the launch of a number of contemporary lifestyle and self-medication products. Their joint venture with DiaMed AG of Switzerland was among the highlights of the year 2004-2005, while 2006-2007 saw them acquire fifty new prospective customers in Korea, Japan and Taiwan. The year 2007-2008 was marked by the company making tie-ups with several new business segments, along with marketing alliances with global players such as Immucor USA, Teco Medical Instruments, and In-Tech, INC.

Share Price: ₹79.89 per share as on 20 Dec, 2024 04:01 PM
Market Capitalisation: ₹4,607.74Cr as of today
Revenue: ₹437.73Cr as on September 2024 (Q3 24)
Net Profit: ₹34.85Cr as on September 2024 (Q3 24)
Listing date: 15 May, 1995
Chairperson Name: Sushil Suri
OrganisationMorepen Laboratories Ltd
HeadquartersGurgaon
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Morepen Laboratories Ltd

  • Dr Morepen Targets Rs 500-Crore Revenue in Wellness - 14 Dec, 2024

    Dr Morepen aims to generate Rs 500 crore from its new wellness category within three to four years, starting with a projected Rs 30 crore in the first year. The company launched a weight management program, LightLife, to tap into the growing wellness market, expected to expand significantly by 2032.
  • Morepen Labs Launches Weight Management Program LightLife - 11 Dec, 2024

    Morepen Labs has introduced LightLife, a weight management program aimed at addressing obesity in India. The initiative combines nutrition products and a health-tracking app, targeting significant revenue growth in the wellness market.
  • Dr. Morepen Launches Weight Management Product - 10 Dec, 2024

    Dr. Morepen, a subsidiary of Morepen Laboratories, has launched LightLife, a weight management solution priced at Rs. 599, targeting health-conscious individuals in India. The product aims to address obesity, supported by a wellness program and available online and in select retail outlets.
  • Morepen Labs Reports Strong Q2 Growth - 25 Nov, 2024

    Morepen Laboratories reported a 3.78% increase in net sales to Rs 437.73 crore for September 2024. Net profit surged 63.95% to Rs 34.85 crore, while EBITDA rose 33.21%. The EPS increased to Rs 0.65. The stock has delivered impressive returns of 45.39% over the last six months and 70.15% over the past year.

Insights on Morepen Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, MOREPENLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 53.72% to 60.56% in Sep 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 135.8% return, outperforming this stock by 67.6%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 35.65% of holdings in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 458.64 Cr → 442.71 Cr (in ₹), with an average decrease of 3.5% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, MOREPENLAB stock has moved down by -4.8%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 36.17 Cr → 34.85 Cr (in ₹), with an average decrease of 3.7% per quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 7.72% to 2.08% in Sep 2024 quarter

Morepen Laboratories Ltd Financials

Value in ₹ crore
DetailsQ'3 23Q'4 23Q'1 24Q'2 24Q'3 24
Revenue₹421.77Cr (-)₹444.55Cr (↑5.40%)₹423.07Cr (↓4.83%)₹455.22Cr (↑7.60%)₹437.73Cr (↓3.84%)
Net Income₹21.26Cr (-)₹31.99Cr (↑50.47%)₹28.74Cr (↓10.16%)₹36.17Cr (↑25.85%)₹34.85Cr (↓3.65%)
Net Profit Margin5.04% (-)7.20% (↑42.86%)6.79% (↓5.69%)7.95% (↑17.08%)7.96% (↑0.13%)
Value in ₹ crore
Details2021202220232024
Total Assets₹847.51Cr (-)₹1,042.45Cr (↑23.00%)₹1,115.11Cr (↑6.97%)₹1,289.69Cr (↑15.66%)
Total Liabilities₹402.54Cr (-)₹444.28Cr (↑10.37%)₹334.99Cr (↓24.60%)₹400.66Cr (↑19.60%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹10.86Cr (-)₹49.31Cr (↑354.05%)-₹68.87Cr (↓239.67%)-₹102.12Cr (↑48.28%)₹77.36Cr (↓175.75%)

Index Inclusions

BSE Healthcare

₹44,095.46

-1.13 (-505.02%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

BSE Small-Cap

₹55,149.22

-2.11 (-1188.47%)

Morepen Laboratories Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
35.65%
0.00
Foreign Institutions
2.08%
-73.12
Mutual Funds
0%
157.14
Retail Investors
60.56%
12.74
Others
1.71%
-41.32

Morepen Laboratories Ltd Key Indicators

Details20202021202220232024
Earning Per Share (₹)0.752.162.130.761.89
Details20202021202220232024
Return On Equity %9.8624.4319.386.7113.29
Details20202021202220232024
Return On Assets %5.0711.469.753.477.46
Details20202021202220232024
Book Value Per Share (₹)6.328.4711.5614.7316.58

Morepen Laboratories Ltd Valuation

Morepen Laboratories Ltd in the last 5 years

  • Overview

  • Trends

Lowest (10.48x)

March 23, 2020

Today (32.91x)

December 19, 2024

Industry (56.23x)

December 19, 2024

Highest (64.70x)

January 22, 2018

LowHigh

Morepen Laboratories Ltd Earnings and Dividends

  • Morepen Laboratories Ltd Earnings Results

    Morepen Laboratories Ltd’s net profit jumped 63.92% since last year same period to ₹34.85Cr in the Q2 2024-2025. On a quarterly growth basis, Morepen Laboratories Ltd has generated -3.65% fall in its net profits since last 3-months.

    Read More about Earnings Results

Morepen Laboratories Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Morepen Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.

FAQs on Morepen Laboratories Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Morepen Laboratories Ltd shares.

Morepen Laboratories Ltd (MOREPENLAB) share price today is ₹79.89

Morepen Laboratories Ltd is listed on NSE

Morepen Laboratories Ltd is listed on BSE

  • Today’s highest price of Morepen Laboratories Ltd is ₹84.57.
  • Today’s lowest price of Morepen Laboratories Ltd is ₹79.06.

PE Ratio of Morepen Laboratories Ltd is 32.91

PE ratio = Morepen Laboratories Ltd Market price per share / Morepen Laboratories Ltd Earnings per share

Today’s traded volume of Morepen Laboratories Ltd(MOREPENLAB) is 54.28L.

Today’s market capitalisation of Morepen Laboratories Ltd(MOREPENLAB) is ₹4607.74Cr.

Morepen Laboratories Ltd(MOREPENLABPrice
52 Week High
₹100.9
52 Week Low
₹38.55

Morepen Laboratories Ltd(MOREPENLAB) share price is ₹79.89. It is down -20.82% from its 52 Week High price of ₹100.9

Morepen Laboratories Ltd(MOREPENLAB) share price is ₹79.89. It is up 107.24% from its 52 Week Low price of ₹38.55

Morepen Laboratories Ltd(MOREPENLABReturns
1 Day Returns
-3.36%
1 Month Returns
13.68%
3 Month Returns
-3.47%
1 Year Returns
72.36%